AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Melanoma: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular MelanomaNCT02678572 · results posted 2026-09-10 · Delcath Systems Inc. · 102 people · tests Melphalan/HDS A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaNCT05625399 · results posted 2026-08-26 · Bristol-Myers Squibb · 579 people · tests Nivolumab + Relatlimab, rHuPH20 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaNCT02224781 · results posted 2026-02-18 · National Cancer Institute (NCI) · 267 people · tests Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaNCT05002569 · results posted 2026-01-08 · Bristol-Myers Squibb · 1093 people · tests Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent n…Ann Oncol 2026 · PMID 42918419 A telomere-to-telomere map of somatic mutation burden and functional impact in a cancer.Cell 2026 · PMID 42880233 Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors.J Clin Oncol 2026 · PMID 42879715 Reading Melanoma's Differentiation State to Settle the Combination Versus Sequencing Debate.J Clin Oncol 2026 · PMID 42848979 Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (IN…Nat Med 2026 · PMID 42823486 Cancer and the microbiome: from association to intervention.Lancet Oncol 2026 · PMID 42805210 Transcriptomic Plasticity and Its Spatial Architecture Shape Melanoma Response to Immunotherapy and Its Combination With BRAF/MEKi.J Clin Oncol 2026 · PMID 42771837 Burden of cancer in Africa, 1990-2023: a systematic analysis from the Global Burden of Disease Study 2023.Lancet Oncol 2026 · PMID 42743938 Recent Population-Level Trends in Utilization of Outpatient Medical Oncology Services.J Clin Oncol 2026 · PMID 42743459 Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis.Science 2026 · PMID 42721225 PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity.Nature 2026 · PMID 42717091

Want these every week? Follow melanoma and get a note on your phone with the new trials and papers.

🔔 Follow melanoma
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy